<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="169752">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00886821</url>
  </required_header>
  <id_info>
    <org_study_id>B1111001</org_study_id>
    <nct_id>NCT00886821</nct_id>
  </id_info>
  <brief_title>A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics</brief_title>
  <official_title>A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Escalating Subcutaneous Doses Of CVX-096 In Type 2 Diabetic Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine safety and tolerability of CVX-096 in adult, type
      2 diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of escalating, subcutaneous doses of CVX-096 administered to adult subjects with T2DM</measure>
    <time_frame>Throughout duration of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics of CVX-096 in serum after administration, under fasting conditions, of escalating, subcutaneous doses of CVX-096 to adult subjects with T2DM</measure>
    <time_frame>Throughout duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacodynamic effect (glucose AUC lowering) of escalating, subcutaneous doses of CVX-096 administered to adult subjects with T2DM</measure>
    <time_frame>Throughout duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect on mean plasma glucose (MPG) after receiving doses of CVX-096</measure>
    <time_frame>Throughout duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess immunogenicity</measure>
    <time_frame>Throughout duration of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CVX-096</intervention_name>
    <description>Subcutaneous administration of CVX-096 with doses ranging from 0.1 mg up to a maximum of 36 mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and/or female patients (females will be women of non-childbearing potential)
             with an historical diagnosis of type 2 diabetes mellitus, who are currently being
             treated with metformin at a dose at or near maximum.

          -  Hb A1c between 7-10%.

          -  Fasting C-peptide &gt;0.4 nmol/L.

        Exclusion Criteria:

          -  History of clinically significant chronic conditions other than T2DM not well
             controlled by either diet or medications.

          -  Patients with pancreatitis or considered a high risk for pancreatitis.

          -  History of contraindications to metformin therapy.

          -  Previous treatment with an approved or investigational GLP 1 mimetic.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Miami Gardens</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1111001&amp;StudyName=A%20Safety%20and%20Pharmacokinetic%20Study%20of%20CVX-096%20in%20Type%202%20Diabetics%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>July 30, 2015</lastchanged_date>
  <firstreceived_date>April 22, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1 Type 2 diabetes CVX-096 diabetes mellitus</keyword>
  <keyword>adult-onset diabetes mellitus</keyword>
  <keyword>non-insulin dependent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
